Accessibility Menu
Arrow-Thin-Down
S&P 500
6,738.44
+0.6%
+39.04
Arrow-Thin-Down
DJI
46,734.61
+0.3%
+144.20
Arrow-Thin-Down
NASDAQ
22,941.80
+0.9%
+201.40
Arrow-Thin-Down
Bitcoin
$111,188
+2.1%
+$2,309.7
Arrow-Thin-Down
AAPL
$259.58
+0.4%
+$1.13
Arrow-Thin-Down
AMZN
$221.09
+1.4%
+$3.14
Arrow-Thin-Down
GOOG
$253.73
+0.5%
+$1.2
Arrow-Thin-Down
META
$734.15
+0.1%
+$0.74
Arrow-Thin-Down
MSFT
$520.56
+0.0%
+$0.02
Arrow-Thin-Down
NVDA
$182.2
+1.1%
+$1.92
Arrow-Thin-Down
TSLA
$448.95
+2.3%
+$9.98
Daily Stock GainersDaily Stock LosersMost Active Stocks

Some price data may be temporarily unavailable.

KEY DATA POINTS

Current Price
$0.00
Daily Change
(-) $0.00
Day's Range
$0.00 - $0.00
Previous Close
$0.00
Open
$0.00
Beta
0
Volume
-
Average Volume
-
Sector
Health Care
Market Cap
-
Market Cap / Employee
-
52wk Range
$0.00 - $0.00
Revenue
-
Gross Margin
-
Dividend Yield
-
EPS
$0.00
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Graphite Bio Company Info

Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services